文献リスト

1) Araki S. Familial amyloidotic polyneuropathy type I. In: Rijswijk MH. Amyloidosis. Dordrecht: The Netherlands Nijhoff. 1986. p.195-218

2) Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan. Neurology. 2002; 58: 1001-7

3) Ando Y, Nakamura M, Araki S, et al. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005; 62: 1057-62

4) Misu K, Hattori N, Nagamatsu M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Brain. 1999; 122: 1951-62

5) Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991; 40: 242-6

6) FAP WTR http:///www.fapwtr.org/

7) Takei Y, Ikeda S, Ikegami T, et al. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: Outcomes of living donor liver transplantations. Intern Med. 2005; 44: 1151-6

8) Ando Y, Tanaka Y, Ando E, et al. Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet. 1995; 345: 195-6

9) Ando Y, Ando E, Tanaka Y, et al. De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation. Transplantation. 1996; 62: 1037-8

10) Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998; 66: 229-33

11) Suhr OB, Friman S, Ericzonet B. Early liver transplantation improves familial amyloidotic polyneuropathy patientsʼ survival. Amyloid. 2005; 12: 233-8

12) Ando Y, Terazaki H, Nakamura M, et al. A different amyloid formation mechanism: De novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation. 2004; 77: 345-9

13) Sakashita N, Ando Y, Haraoka K, et al. Severe congestive heart failure with cardiac liver cirrhosis 10 years after orthotopic liver transplantation for familial amyloidotic polyneuropathy. Pathol Int. 2006; 56: 408-12

14) Ando E, Ando Y, Haraoka K. Ocular amyloid imvolvement after liver transplantation for polyneuropathy. Ann Intern Med. 2001; 135: 931-2

15) Stangou AJ, Heaton ND, Hawkins PN, et al. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005; 352: 2356

16) Goto T, Yamashita T, Ueda M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant. 2006; 6: 2512-5

17) Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid. 1998; 5: 288-300

18) Ando E, Ando Y, Okumura R, et al. Ocular manifestations of familial amyloidotic polyneu-ropathy type I: long-term follow up. Br J Ophthalmol. 1997; 81: 295-8

19) Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006; 13: 236-49

20) Sekijima Y, Tojo K, Morita H, et al. Long-term effects of diflunisal on familial amyloid polyneuropathy. The VIIth international symposium on familial amyloidotic polyneuropathy (abtract). London: 2008. p.5-6

21) Berk JL, Dyck PJ, Obici L, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2010; 17(Suppl 1): 78

22) Waddington-Cruz M, Coelho T, Maia L, et al. A landmark clinical trial of a novel small molecule transthyretin (TTR) stabilizer, Fx-1006A, in patients with TTR amyloid polyneuropathy: a phase II/III, randomized, double-blind, placebo-controlled study. J Neurol. 2008; 255(Suppl 2): 107

23) Sato T, Ando Y, Susuki S, et al. Chromium (III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS lett. 2006; 580: 491-6

24) Nakamura M, Ando Y, Nagahara S, et al. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther. 2004; 11: 838-46

25) Ando Y. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol. 2005; 38: 142-54

26) Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006; 33: 609-18

27) Kurosawa T, Igarashi S, Nishizawa M, et al. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun. 2005; 337: 1012-8

28) Terazaki H, Ando Y, Fernandes R, et al. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest. 2006; 86: 23-31

29) Bergström J, Engström U, Yamashita T, et al. Surface exposed epitopes and structural heterogeneity of in vivo formed transthyretin amyloid fibrils. Biochem Biopys Res Commun. 2006; 348: 532-9

30) Ando Y, Nakamura M, Ueda M, et al. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP). In: Richardoson SJ, Cody V. Recent advances in transthyretin evolution, structure, and biological functions. Berlin Heidelberg: Springer-Verlag; 2009. p.215-38

31) Ueda M, Ando Y, Hakamata Y. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms. Biochem Biophys Res Commun. 2007; 352: 299-304

32) ZMacedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biophys Acta. 2008; 1782: 517-22

33) Kawaji T, Ando Y, Hara R, et al. Novel therapy for transthyretin-related ocular amyloidosis: a pilot study of retinal laser photocoagulation. Ophthalmology. 2010; 117: 552-5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp